Safety of fluoroquinolones in pediatric patients: Pharmacovigilance database analysis
International Journal of Risk & Safety in Medicine · 2025
DOI: 10.1177/09246479251398995 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Risk & Safety in Medicine, 2025. Verfasst von Olga Butranova und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of General and Clinical Pharmacology, Peoples' Friendship University of Russia Named After Patrice Lumumba (RUDN), Moscow, Russia. Hauptthemen laut MEDLINE: Pharmacovigilance, Fluoroquinolones, Anti-Bacterial Agents, Drug-Related Side Effects and Adverse Reactions. Die Arbeit nennt 45 Literaturangaben.
Abstract (Originalsprache)
Background
Due to the rising prevalence of resistant bacteria, there is a growing tendency to prescribe fluoroquinolones (FQs) to pediatric patients. Real world safety parameters of FQs in children may be studied using data of national pharmacovigilance databases. The aim of our study was to estimate the structure of adverse drug reactions (ADR) associated with FQs in pediatric patients. Materials and methods retrospective study of spontaneous reports registered in Russian National Pharmacovigilance database–Automatized Information System “Pharmacovigilance” for the period: 1 April 2019–31 January 2024.
Results
Total number of pediatric SRs was 280 (19.2%). Mean age was 12.1 ± 5.9 years (min – 1 day, max – 18 years), and adolescents were the most involved age group ( n = 176, 62.9%). Mean time to ADR onset was 13.9 + 41.0 (min = 0, max = 303) days. Leading FQs were levofloxacin (49.6%, n = 139), ciprofloxacin (31.1%, n = 87), and moxifloxacin (15%, n = 42). Top-5 SOCs included “Immune disorders” (18.9%), “Gastrointestinal disorders” (15.0%), “Skin and subcutaneous tissue disorders” (14.7%), “General disorders and administration site conditions” (11.7%), and “Investigations” (7.6%). Top-5 PTs were urticaria, diarrhea, rash, arthralgia, and pruritus.
Conclusions
Levofloxacin, ciprofloxacin, and moxifloxacin were the primary FQs linked to ADRs in the pediatric population. Most prevalent were allergic reactions. Children receiving FQs should be closely monitored from the start of treatment throughout their entire hospital stay and for an extended period following discharge.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of General and Clinical Pharmacology, Peoples' Friendship University of Russia Named After Patrice Lumumba (RUDN), Moscow, Russia.
- Moscow City Health Department, City Clinical Hospital No. 24, State Budgetary Institution of Healthcare of the City of Moscow, Moscow, Russia.
- Pharmacovigilance Center, Information and Methodological Center for Expert Evaluation, Record and Analysis of Circulation of Medical Products Under the Federal Service for Surveillance in Healthcare, Moscow, Russia.
ORCID-Profile: Yury Kustov
Zitieren
APA
Butranova, O., Kustov, Y., Zyryanov, S., Asetskaya, I., Terehina, E., Polivanov, V., & Putsman, G. (2025). Safety of fluoroquinolones in pediatric patients: Pharmacovigilance database analysis. International Journal of Risk & Safety in Medicine. https://doi.org/10.1177/09246479251398995
Vancouver
Butranova O, Kustov Y, Zyryanov S, Asetskaya I, Terehina E, Polivanov V, et al. Safety of fluoroquinolones in pediatric patients: Pharmacovigilance database analysis. International Journal of Risk & Safety in Medicine. 2025. doi:10.1177/09246479251398995
BibTeX
@article{Butranova2025,
author = {Butranova, Olga and Kustov, Yury and Zyryanov, Sergey and Asetskaya, Irina and Terehina, Elizaveta and Polivanov, Vitaly and Putsman, Gleb},
title = {Safety of fluoroquinolones in pediatric patients: Pharmacovigilance database analysis},
journal = {International Journal of Risk & Safety in Medicine},
year = {2025},
doi = {10.1177/09246479251398995}
}
EUVIMED